Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20501)	5/11/1998 7:37:00 PM
From: Mudcat	Read Replies (1) \| Respond to of 32384

Seems like an awful lot of money for a company that was almost out of business. I sure hope Robinson knows something good about Seragen's technology that we on the thread don't.

To: Henry Niman who wrote (20501)	5/11/1998 9:04:00 PM
From: squetch	Read Replies (1) \| Respond to of 32384

Henry, >>The remainder of the $37 million payment will be used to settle claims of Seragen's creditors and preferred shareholders.<<SRGN has a 5million obligation to who I forgot for advanced future sales. Is this part of that 37? Now they sold their manufacturing and clinical operations to Boston University back in 2/97. I read it as they have a lease obligation to BU. So that is probably part of the 37. SRGN has the right to repurchase those assets from BU. I wonder if this is part of the 37? Where are those people gonna work otherwise. Also in the its not all there file, those who said you aren't I beat you to it(:>), US Surgical still appears to have rights to restenosis after angio. squetch

To: Henry Niman who wrote (20501)	6/1/1998 5:30:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< "We believe that ONTAK represents an important therapeutic option for patients with CTCL and their physicians, and we look forward to our upcoming review with the ODAC," said Jean Nichols, Ph.D., Seragen President and Chief Technology Officer. "We are pleased that if successful in gaining FDA approval, we will be able to provide through Ligand a rapid availability of ONTAK to CTCL patients in the U.S. and abroad, a goal many of us at Seragen have pursued for many years." >> Many years of work went into the development of ONTAK. Tomorrow is a big day for those who have worked on it. << If approved, ONTAK will be recognized as the first of a new class of cytotoxic biologic agents - a fusion protein. >> Here's hoping that the ODAC gives a favorable ruling. ONTAK could open the door to many other products. By the way, I just visited your website, again. I wanted to find out more info about tomorrow's ODAC meetings, and had no problems locating what I was looking for. Ligand should give you royalties on their products! <g> Good luck, Bob